New study shows Nevisense significantly improves US clinician’s decision-making beyond dermoscopy
STOCKHOLM, SWEDEN, — October 26, 2022 – SciBase Holding AB (“SciBase”) [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that a new clinical study has been published presenting the improvement that the Nevisense test provides over standard of care visual and dermoscopic evaluation. The article named “Electrical impedance spectroscopy significantly enhances correct biopsy choice for pigmented skin lesions beyond clinical evaluation and dermoscopy” has been published in the journal “Melanoma Research”. The study included 231 US